Novo Nordisk A/S
NVO
$78.11
-$0.84-1.06%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.86% | 27.74% | 31.76% | 34.73% | 34.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.86% | 27.74% | 31.76% | 34.73% | 34.69% |
| Cost of Revenue | 23.21% | 22.41% | 29.06% | 29.67% | 27.45% |
| Gross Profit | 25.16% | 28.74% | 32.26% | 35.68% | 36.08% |
| SG&A Expenses | 9.22% | 14.78% | 14.91% | 22.62% | 24.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -8.33% | 92.85% | 50.61% | 127.72% | 58.48% |
| Total Operating Expenses | 17.85% | 21.15% | 24.79% | 29.11% | 29.29% |
| Operating Income | 33.41% | 36.22% | 40.92% | 42.09% | 41.91% |
| Income Before Tax | 21.44% | 29.07% | 38.99% | 52.81% | 55.17% |
| Income Tax Expenses | 24.76% | 37.11% | 46.61% | 58.53% | 58.46% |
| Earnings from Continuing Operations | 20.61% | 27.14% | 37.16% | 51.42% | 54.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.61% | 27.14% | 37.16% | 51.42% | 54.37% |
| EBIT | 33.41% | 36.22% | 40.92% | 42.09% | 41.91% |
| EBITDA | 32.86% | 35.42% | 41.02% | 41.97% | 40.27% |
| EPS Basic | 21.37% | 28.09% | 38.34% | 52.90% | 56.07% |
| Normalized Basic EPS | 30.62% | 36.58% | 47.49% | 54.46% | 57.03% |
| EPS Diluted | 21.47% | 28.16% | 38.32% | 52.89% | 56.08% |
| Normalized Diluted EPS | 30.71% | 36.67% | 47.57% | 54.53% | 57.07% |
| Average Basic Shares Outstanding | -0.64% | -0.78% | -0.90% | -0.98% | -1.06% |
| Average Diluted Shares Outstanding | -0.72% | -0.85% | -0.96% | -1.02% | -1.08% |
| Dividend Per Share | 19.95% | 43.18% | 43.18% | 57.68% | 57.68% |
| Payout Ratio | 0.16% | 0.10% | 0.13% | 0.02% | -0.19% |
